Is CNTA or DMRA more profitable?

Centessa Pharmaceuticals' return on equity of -60.37% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Centessa Pharmaceuticals N/A -60.37% -44.17% Damora Therapeutics, Inc. Common Stock N/A -428.30% -114.62%

Which has higher valuation and earnings, COGT or DMRA?

Cogent Biosciences is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cogent Biosciences N/A N/A -$328.94M -$2.17 N/A Damora Therapeutics, Inc. Common Stock N/A N/A -$209.84M -$5.58 N/A

Is COGT or DMRA more profitable?

Cogent Biosciences' return on equity of -104.27% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -104.27% -54.64% Damora Therapeutics, Inc. Common Stock N/A -428.30% -114.62%

Which has stronger earnings and valuation, BLTE or DMRA?

Belite Bio is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Belite Bio N/A N/A -$77.61M -$2.53 N/A Damora Therapeutics, Inc. Common Stock N/A N/A -$209.84M -$5.58 N/A

Is BLTE or DMRA more profitable?

Belite Bio's return on equity of -13.14% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Belite Bio N/A -13.14% -12.88% Damora Therapeutics, Inc. Common Stock N/A -428.30% -114.62%

Damora Therapeutics, Inc. Common Stock (DMRA) Competitors

$20.15 -0.81 (-3.86%)

As of 04:00 PM Eastern

Compare

DMRA vs. PTGX, RYTM, CNTA, COGT, and BLTE

Should you buy Damora Therapeutics, Inc. Common Stock stock or one of its competitors? MarketBeat compares Damora Therapeutics, Inc. Common Stock with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Damora Therapeutics, Inc. Common Stock include Protagonist Therapeutics (PTGX), Rhythm Pharmaceuticals (RYTM), Centessa Pharmaceuticals (CNTA), Cogent Biosciences (COGT), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical products" industry.

How does Damora Therapeutics, Inc. Common Stock compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

Protagonist Therapeutics presently has a consensus target price of $115.21, suggesting a potential upside of 8.93%. Damora Therapeutics, Inc. Common Stock has a consensus target price of $42.00, suggesting a potential upside of 108.44%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher possible upside, analysts plainly believe Damora Therapeutics, Inc. Common Stock is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by company insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Protagonist Therapeutics had 3 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 5 mentions for Protagonist Therapeutics and 2 mentions for Damora Therapeutics, Inc. Common Stock. Protagonist Therapeutics' average media sentiment score of 1.47 beat Damora Therapeutics, Inc. Common Stock's score of 1.43 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Protagonist Therapeutics	Positive
Damora Therapeutics, Inc. Common Stock	Positive

Damora Therapeutics, Inc. Common Stock has a net margin of 0.00% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%

Protagonist Therapeutics has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	147.81	-$130.15M	-$1.81	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A

Protagonist Therapeutics has a beta of 1.85, indicating that its stock price is 85% more volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market.

Summary

Protagonist Therapeutics beats Damora Therapeutics, Inc. Common Stock on 11 of the 16 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are held by insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Rhythm Pharmaceuticals has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	30.95	-$196.54M	-$3.13	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A

Rhythm Pharmaceuticals presently has a consensus price target of $131.81, indicating a potential upside of 53.79%. Damora Therapeutics, Inc. Common Stock has a consensus price target of $42.00, indicating a potential upside of 108.44%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher probable upside, analysts plainly believe Damora Therapeutics, Inc. Common Stock is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

In the previous week, Rhythm Pharmaceuticals had 1 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 3 mentions for Rhythm Pharmaceuticals and 2 mentions for Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 1.43 beat Rhythm Pharmaceuticals' score of 0.47 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the news media.

Company	Overall Sentiment
Rhythm Pharmaceuticals	Neutral
Damora Therapeutics, Inc. Common Stock	Positive

Rhythm Pharmaceuticals has a beta of 1.91, suggesting that its stock price is 91% more volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market.

Damora Therapeutics, Inc. Common Stock has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Rhythm Pharmaceuticals' return on equity of -203.25% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%

Summary

Rhythm Pharmaceuticals beats Damora Therapeutics, Inc. Common Stock on 9 of the 16 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to Centessa Pharmaceuticals?

Centessa Pharmaceuticals (NASDAQ:CNTA) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. Comparatively, 14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. 4.1% of Centessa Pharmaceuticals shares are owned by company insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Centessa Pharmaceuticals has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market.

Centessa Pharmaceuticals currently has a consensus target price of $41.33, indicating a potential upside of 4.14%. Damora Therapeutics, Inc. Common Stock has a consensus target price of $42.00, indicating a potential upside of 108.44%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher possible upside, analysts clearly believe Damora Therapeutics, Inc. Common Stock is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

In the previous week, Centessa Pharmaceuticals had 2 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 4 mentions for Centessa Pharmaceuticals and 2 mentions for Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 1.43 beat Centessa Pharmaceuticals' score of 0.93 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the news media.

Company	Overall Sentiment
Centessa Pharmaceuticals	Positive
Damora Therapeutics, Inc. Common Stock	Positive

Centessa Pharmaceuticals has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	$15M	394.86	-$197.53M	-$1.79	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A

Centessa Pharmaceuticals' return on equity of -60.37% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%

Summary

Centessa Pharmaceuticals beats Damora Therapeutics, Inc. Common Stock on 8 of the 15 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

Cogent Biosciences' return on equity of -104.27% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%

14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. 6.6% of Cogent Biosciences shares are owned by insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Cogent Biosciences is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A

Cogent Biosciences has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market.

Cogent Biosciences presently has a consensus price target of $43.73, indicating a potential upside of 39.35%. Damora Therapeutics, Inc. Common Stock has a consensus price target of $42.00, indicating a potential upside of 108.44%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher probable upside, analysts clearly believe Damora Therapeutics, Inc. Common Stock is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

In the previous week, Cogent Biosciences had 3 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 5 mentions for Cogent Biosciences and 2 mentions for Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 1.43 beat Cogent Biosciences' score of 1.09 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the news media.

Company	Overall Sentiment
Cogent Biosciences	Positive
Damora Therapeutics, Inc. Common Stock	Positive

Summary

Damora Therapeutics, Inc. Common Stock beats Cogent Biosciences on 7 of the 13 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

Belite Bio presently has a consensus target price of $203.00, suggesting a potential upside of 48.59%. Damora Therapeutics, Inc. Common Stock has a consensus target price of $42.00, suggesting a potential upside of 108.44%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher probable upside, analysts plainly believe Damora Therapeutics, Inc. Common Stock is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

In the previous week, Belite Bio and Belite Bio both had 2 articles in the media. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 1.43 beat Belite Bio's score of 0.47 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the news media.

Company	Overall Sentiment
Belite Bio	Neutral
Damora Therapeutics, Inc. Common Stock	Positive

Belite Bio's return on equity of -13.14% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-13.14%	-12.88%
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%

0.5% of Belite Bio shares are held by institutional investors. Comparatively, 14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. 13.3% of Belite Bio shares are held by company insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Belite Bio is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A

Belite Bio has a beta of -1.24, suggesting that its share price is 224% less volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market.

Summary

Damora Therapeutics, Inc. Common Stock beats Belite Bio on 7 of the 12 factors compared between the two stocks.

Get Damora Therapeutics, Inc. Common Stock News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DMRA vs. The Competition

Export

Metric	Damora Therapeutics, Inc. Common Stock	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.24B	$3.28B	$6.43B	$11.71B
Dividend Yield	N/A	2.33%	2.67%	5.55%
P/E Ratio	-3.61	18.99	24.49	23.62
Price / Sales	N/A	290.48	500.49	105.27
Price / Cash	N/A	118.24	42.36	56.09
Price / Book	-0.18	8.00	10.43	6.70
Net Income	-$209.84M	$23.89M	$3.56B	$337.26M
7 Day Performance	-9.92%	-3.49%	-1.38%	-1.41%
1 Month Performance	-16.60%	1.02%	0.86%	1.15%
1 Year Performance	499.70%	34.39%	19.43%	22.61%

Damora Therapeutics, Inc. Common Stock Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DMRA Damora Therapeutics, Inc. Common Stock	2.7425 of 5 stars	$20.15 -3.9%	$42.00 +108.4%	+537.1%	$1.24B	N/A	N/A	40	Positive News Analyst Forecast
PTGX Protagonist Therapeutics	1.8501 of 5 stars	$93.19 -1.8%	$115.21 +23.6%	+90.1%	$6.10B	$46.02M	N/A	120	Positive News
RYTM Rhythm Pharmaceuticals	2.7876 of 5 stars	$84.35 -4.0%	$131.81 +56.3%	+31.7%	$6.02B	$189.76M	N/A	140
CNTA Centessa Pharmaceuticals	1.7004 of 5 stars	$39.90 +0.1%	$41.33 +3.6%	+233.0%	$5.95B	$15M	N/A	200	News Coverage Positive News
COGT Cogent Biosciences	2.9428 of 5 stars	$32.76 -5.9%	$43.73 +33.5%	+363.5%	$5.95B	N/A	N/A	80	News Coverage High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DMRA) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Damora Therapeutics, Inc. Common Stock (DMRA) Competitors

DMRA vs. PTGX, RYTM, CNTA, COGT, and BLTE

How does Damora Therapeutics, Inc. Common Stock compare to Protagonist Therapeutics?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Rhythm Pharmaceuticals?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Centessa Pharmaceuticals?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Cogent Biosciences?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Belite Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMRA vs. The Competition

Damora Therapeutics, Inc. Common Stock Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Damora Therapeutics, Inc. Common Stock (DMRA) Competitors

DMRA vs. PTGX, RYTM, CNTA, COGT, and BLTE

How does Damora Therapeutics, Inc. Common Stock compare to Protagonist Therapeutics?

Do analysts recommend PTGX or DMRA?

Do insiders & institutionals hold more shares of PTGX or DMRA?

Does the media prefer PTGX or DMRA?

Is PTGX or DMRA more profitable?

Which has stronger valuation and earnings, PTGX or DMRA?

Which has more volatility & risk, PTGX or DMRA?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Rhythm Pharmaceuticals?

Do insiders and institutionals believe in RYTM or DMRA?

Which has better earnings & valuation, RYTM or DMRA?

Do analysts rate RYTM or DMRA?

Does the media prefer RYTM or DMRA?

Which has more volatility & risk, RYTM or DMRA?

Is RYTM or DMRA more profitable?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Centessa Pharmaceuticals?

Do insiders & institutionals believe in CNTA or DMRA?

Which has more volatility & risk, CNTA or DMRA?

Do analysts prefer CNTA or DMRA?

Does the media prefer CNTA or DMRA?

Which has better earnings and valuation, CNTA or DMRA?

Is CNTA or DMRA more profitable?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Cogent Biosciences?

Is COGT or DMRA more profitable?

Do insiders and institutionals believe in COGT or DMRA?

Which has higher valuation and earnings, COGT or DMRA?

Which has more risk and volatility, COGT or DMRA?

Do analysts prefer COGT or DMRA?

Does the media prefer COGT or DMRA?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Belite Bio?

Do analysts recommend BLTE or DMRA?

Does the media prefer BLTE or DMRA?

Is BLTE or DMRA more profitable?

Do insiders and institutionals hold more shares of BLTE or DMRA?

Which has stronger earnings and valuation, BLTE or DMRA?

Which has more risk & volatility, BLTE or DMRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMRA vs. The Competition

Damora Therapeutics, Inc. Common Stock Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools